L-glutamate is an important component of protein. It can prevent gastrointestinal damage caused by NSAIDs. We constructed two-phase enteric-coated granules of aspirin and L-glutamate compound by extrusion spheronization method and fluidized bed coating. The subliminal effective dose of L-glutamate is 100 mg/kg tested by model of gastric ulcer of rats induced by aspirin and drug administration. HPLC-UV and UV–Vis methods were adopted to determine content and cumulative release of aspirin and L-glutamate as quality analysis method indexes. The prescription and process optimization were carried out with yield, sphericity and dissolution. The two-phase compound granules have good sphericity of 0.93 ± 0.05 (aspirin pellets) and 0.94 ± 0.02 (L-glutamate pellets), content of salicylic acid (0.24 ± 0.03)%, dissolution of aspirin (2.36 ± 0.11)%. Quality evaluation and preliminary stability meet the commercial requirements. The stored environment of compound preparation should be sealed in a cool and dark place.

L-谷氨酸是蛋白质的重要​​成分。它可以防止非甾体抗炎药引起的胃肠道损伤。我们通过挤压滚圆法和流化床包衣法构建了阿司匹林和L-谷氨酸复合物的两相肠溶颗粒。L-谷氨酸的阈下有效剂量为100mg/kg，通过阿司匹林致大鼠胃溃疡模型和给药试验。采用HPLC-UV和UV-Vis法测定阿司匹林和L-谷氨酸的含量和累积释放量作为质量分析方法指标。对收率、球形度和溶出度进行处方和工艺优化。两相复方颗粒具有良好的球形度，分别为0.93±0.05（阿司匹林微丸）和0.94±0.02（L-谷氨酸微丸），水杨酸含量（0.24±0.03）%，阿司匹林溶出度（2.36±0.11）%。质量评价和初步稳定性符合商业要求。复方制剂的储存环境应密封于阴凉避光处。